Takeda and Sanofi join Milner Therapeutics Consortium
The Milner Therapeutics Institute are excited to announce that two new pharma partners — Takeda and Sanofi — have joined the Milner Consortium in the past month.
Now with 14 pharma partners and 3 academic partners, this is the largest cross-sector Biomedical Consortia in the UK that is working in target discovery across multiple disease areas and emerging technologies. Since 2015, the Consortium has initiated 37 research projects across the University of Cambridge, Babraham and Wellcome Sanger Institutes, bringing a research investment of over £9m.
Sanofi has its UK R&D base on the Babraham Research Campus, south of Cambridge, which is focused on the discovery of novel therapeutics for the treatment of chronic inflammatory and autoimmune diseases, and also brings expertise around antibody discovery and antibody engineering. Chris Schiering (Director of Translational Biology, Immune Regulation & Tolerance Cluster, I&I Research) and Mark Peakman (Head of Immune Regulation & Tolerance Cluster, I&I Research) will represent Sanofi on the Milner Innovation Board.
Takeda aims to discover and deliver life-transforming treatments in core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Takeda’s global Research and Development (R&D) center is based in Cambridge, Massachusetts with R&D Research Labs in San Diego, California, and Shonan, Japan and Regional R&D Centers and local sites across the globe. Peter Maycox (Director of External Innovation, Neuroscience Research) will represent Takeda on the Milner Innovation Board with an additional representative joining in the coming months.
More news and updates